DNA X, Inc.
For the period ended Dec 31, 2025. Filed Apr 15, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 15, 2026
SONM$2.35+5.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets – At December 31, 2025 and 2024
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2025 and 2024
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Cash and cash equivalents | $1,303 | $5,343 |
| Prepaid expenses and other current assets | 676 | — |
| Current assets held for sale | 26,930 | 26,822 |
| Total Current assets | 28,909 | 32,165 |
| Investment in DNA X, LLC | 1,242 | — |
| Deferred tax assets | 1,441 | 64 |
| Other assets | 274 | 384 |
| Non-current assets held for sale | 12,032 | 7,126 |
| Total assets | $43,898 | $39,739 |
| Liabilities and stockholders’ deficit | ||
| Accounts payable | 4,030 | 738 |
| Accrued liabilities | 704 | 250 |
| Promissory notes, net | 5,065 | — |
| Derivative liability on convertible note | 171 | — |
| Current liabilities held for sale | 38,057 | 42,752 |
| Total current liabilities | 48,027 | 43,740 |
| Income tax payable | 2,598 | 1,699 |
| Total liabilities | 50,625 | 45,439 |
| Commitments and contingencies (Note 9) | — | — |
| Redeemable common stock, $0.001 par value; 223,201 shares issued and outstanding; redemption value $1,228 (Note 6) | 1,228 | — |
| Stockholders’ deficit | ||
| Common stock, $0.001 par value per share; 1,000,000,000 shares authorized: and 1,265,067 and 276,881 shares issued and outstanding at December 31, 2025 and 2024, respectively* | 1 | — |
| Preferred stock, $0.001 par value per share, 5,000,000 shares authorized: and no shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Additional paid-in capital* | 296,309 | 277,908 |
| Accumulated deficit | (304,265) | (283,608) |
| Total stockholders’ deficit | (7,955) | (5,700) |
| Total liabilities, redeemable common stock, and stockholders’ deficit | $43,898 | $39,739 |
| * | Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025, see Note 1. |
|---|
The accompanying notes are an integral part of these consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.